Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor α production by rheumatoid synoviocytes
Mi-La Cho
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorWan-Uk Kim
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorSo-Youn Min
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorDo-June Min
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorJun-Ki Min
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorSang-Heon Lee
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorSung-Hwan Park
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorChul-Soo Cho
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorCorresponding Author
Ho-Youn Kim
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
The Center for Rheumatic Diseases in Kang-Nam St. Mary's Hospital, Division of Rheumatology, Department of Internal Medicine, Catholic University of Korea School of Medicine, No. 505 Banpo-Dong, Seocho-Ku, Seoul 137-040, South KoreaSearch for more papers by this authorMi-La Cho
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorWan-Uk Kim
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorSo-Youn Min
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorDo-June Min
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorJun-Ki Min
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorSang-Heon Lee
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorSung-Hwan Park
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorChul-Soo Cho
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
Search for more papers by this authorCorresponding Author
Ho-Youn Kim
The Center for Rheumatic Diseases in Kang-Nam St. Mary' Hospital, and Research Institute of Immunobiology, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, South Korea
The Center for Rheumatic Diseases in Kang-Nam St. Mary's Hospital, Division of Rheumatology, Department of Internal Medicine, Catholic University of Korea School of Medicine, No. 505 Banpo-Dong, Seocho-Ku, Seoul 137-040, South KoreaSearch for more papers by this authorAbstract
Objective
To determine the direct effect of cyclosporin A (CSA) on the production of cytokines by rheumatoid synovial fibroblasts.
Methods
Fibroblast-like synoviocytes (FLS) were prepared from the synovial tissues of patients with rheumatoid arthritis and cultured in the presence of CSA. The production of interleukin-10 (IL-10), IL-15, and tumor necrosis factor α (TNFα) by FLS was measured in culture supernatants by enzyme-linked immunosorbent assay. The expression of IL-10, IL-15, and TNFα messenger RNA (mRNA) in FLS was determined by polymerase chain reaction (PCR).
Results
CSA (1–1,000 ng/ml) increased the production of IL-10, but decreased in a dose-dependent manner the levels of IL-15 and TNFα that were spontaneously secreted from FLS. CSA also potently inhibited the production of IL-15 and TNFα stimulated with interferon-γ, IL-1β, or lipopolysaccharide. The inhibitory effect of CSA on IL-15 and TNFα production depended on the increase in IL-10, since neutralizing anti-IL-10 antibodies were able to partially reverse this inhibition. In a semiquantitative PCR, CSA increased IL-10 mRNA expression but strongly suppressed IL-1β-induced IL-15 and TNFα mRNA expression, indicating that the production of these cytokines by CSA was regulated at the transcriptional level. Results with the calcineurin inhibitor FK-506, but not with the immunosuppressant rapamycin, were similar to those with CSA. Agonists of cAMP displayed an additive effect on the changes produced in the IL-10, IL-15, and TNFα levels by CSA, while a cAMP antagonist almost completely abrogated the effect of CSA, suggesting that cAMP is the major intracellular signal that mediates cytokine regulation by CSA.
Conclusion
These results suggest that CSA differentially regulates the production of cytokines by rheumatoid synoviocytes via a cAMP-dependent pathway.
REFERENCES
- 1 Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151–60.
- 2 McInnes IB, Liew FY. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998; 19: 75–9.
- 3 Brennan FM, Maini RN, Feldmann M. TNF-α: a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293–8.
- 4 Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163–8.
- 5 Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7.
- 6 McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 1997; 3: 189–95.
- 7 Sebbag M, Parry SL, Brennan FM, Feldmann M. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-α, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 1997; 27: 624–32.
- 8 Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444–51.
- 9 Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815–22.
- 10 Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr.. Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J Biol Chem 1999; 274: 31868–74.
- 11 Valmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39: 495–503.
- 12 Verhoef CM, van Roon JA, Vianen ME, Lafeber FP, Bijlsma JW. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann Rheum Dis 1999; 58: 49–54.
- 13 Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994; 179: 1517–27.
- 14 Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137–41.
- 15 Timmerman LA, Clipstone NA, Ho SN, Northrop JP, Crabtree GR. Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression. Nature 1996; 383: 837–40.
- 16 Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A, et al. Cyclosporin A interferes with the inducible degradation of NF-κB inhibitors, but not with the processing of p105/NF-κB1 in T cells. Eur J Immunol 1997; 27: 1601–9.
- 17 Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK 506 and cyclosporine A on cytokine production studied in vitro at single cell level. Immunology 1992; 75: 136–42.
- 18 Bonnotte B, Pardoux C, Bourhis JH, Caignard A, Burdiles AM, Chehimi J, et al. Inhibition of human allogeneic mixed lymphocyte response by cyclosporine A: relationship with IL-12 pathway. Tissue Antigens 1996; 48: 265–70.
- 19 Kim WU, Cho ML, Kim SI, Yoo WH, Lee SS, Joo YS, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol 2000; 27: 324–31.
- 20 Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992; 127: 5–24.
- 21 Bouaboula M, Legoux P, Pessegue B, Delpech B, Dumont X, Piechaczyk M, et al. Standardization of mRNA titration using a polymerase chain reaction method involving co-amplification with a multispecific internal control. J Biol Chem 1992; 267: 21830–8.
- 22 Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136–42.
- 23 Crabtree GR, Clipstone NA. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 1994; 63: 1045–83.
- 24 Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000; 57: 437–48.
- 25 Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 1998; 63: 101–7.
- 26 Van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181: 775–9.
- 27
Platzer C,
Fritsch E,
Elsner T,
Lehmann MH,
Volk HD,
Prosch S.
Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells.
Eur J Immunol
1999;
29:
3098–104.
10.1002/(SICI)1521-4141(199910)29:10<3098::AID-IMMU3098>3.0.CO;2-H CAS PubMed Web of Science® Google Scholar
- 28 Ollivier V, Parry GCN, Cobb RR, de Prost D, Mackman N. Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 1996; 271: 20828–35.
- 29 Parry GC, Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-κB-mediated transcription. J Immunol 1997; 159: 5450–6.
- 30 Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum 1996; 39: 1781–90.
- 31 Bucala R, Ritchlin C, Winchester R, Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med 1991; 173: 569–74.
- 32 Bédard PA, Golds EE. Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblasts. J Cell Physiol 1993; 154: 433–41.
- 33 Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1096–105.
- 34 Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997; 40: 2105–15.
- 35 Harada S, Yamamura M, Okamoto H, Morita Y, Kawashima M, Aita T, et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 1508–16.
- 36 Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α. Arthritis Rheum 1996; 39: 197–203.
- 37 Rödel J, Straube E, Lungershausen W, Hartmann M, Groh A. Secretion of cytokines by human synoviocytes during in vitro infection with Chlamydia trachomatis. J Rheumatol 1998; 25: 2161–8.
- 38 Ritchlin C, Haas-Smith SA. Expression of IL-10 mRNA and protein by synovial fibroblastoid cells. J Rheumatol 2001; 28: 698–705.
- 39 Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE. Tumor necrosis factor-α is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci U S A 1994; 91: 7007–11.
- 40 Tsai EY, Yie J, Thanos D, Goldfeld AE. Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol 1996; 16: 5232–44.
- 41 Cockfield SM, Ramassar V, Halloran PF. Regulation of IFN-γ and tumor necrosis factor-α expression in vivo: effects of cycloheximide and cyclosporine in normal and lipopolysaccharide-treated mice. J Immunol 1993; 150: 342–52.
- 42 Durez P, Abramowicz D, Gerard C, Van Mechelen M, Amraoui Z, Dubois C, et al. In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J Exp Med 1993; 177: 551–5.
- 43 Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000; 43: 2619–33.
- 44 Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497–504.
- 45 Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749–52.
- 46 Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65–70.
- 47 Perna A, Gotti E, de Bernardis E, Perico N, Remuzzi G. Alogistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. J Am Soc Nephrol 1996; 7: 786–91.
- 48 Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999; 68: 1839–42.
- 49 Maini RN, Paulus H, Breedveld FC, Moreland LW, William St. Clair E, Russell AS, et al. rHUIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study [abstract]. Arthritis Rheum 1997; 40 Suppl 9: S224.
- 50 Dumont FJ, Staruch MJ, Fischer P, DaSilva C, Camacho R. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol 1998; 160: 2579–89.
- 51 Li B, Sehajpal PK, Khanna A, Vlassara H, Cerami A, Stenzel KH, et al. Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 1991; 174: 1259–62.
- 52 Van der Pouw Kraan TC, Boeije LC, Troon JT, Rutschmann SK, Wijdenes J, Aarden LA. Human IL-13 production is negatively influenced by CD3 engagement: enhancement of IL-13 production by cyclosporin A. J Immunol 1996; 156: 1818–23.
- 53 Aicher WK, Dinkel A, Grimbacher B, Haas C, Seydlitz-Kurzbach EV, Peter HH, et al. Serum response elements activate and cAMP responsive elements inhibit expression of transcription factor Egr-1 in synovial fibroblasts of rheumatoid arthritis patients. Int Immunol 1999; 11: 47–61.
- 54 Case JP, Lafyatis R, Kumkumian GK, Remmers EF, Wilder RL. IL-1 regulation of transin/stromelysin transcription in rheumatoid synovial fibroblasts appears to involve two antagonistic transduction pathways, an inhibitory, prostaglandin-dependent pathway mediated by cAMP, and a stimulatory, protein kinase C-dependent pathway. J Immunol 1990; 145: 3755–61.
- 55 Boyle DL, Sajjadi FG, Firestein GS. Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 1996; 39: 923–30.
- 56 Khabar KS, Dzimiri M, Parhar RS, Siddiqui S, Einspenner M, Al-Humaidan A, et al. Pentoxifylline (PTX) selectively potentiates cyclosporine (CSA)-mediated suppression of cell-mediated lymphocytotoxicity: median-effect analysis for the drug dose reductions in PTX and CSA combination treatment. Transplantation 1996; 61: 838–41.
- 57 Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Rajotte RV, Power RF. Combination therapy with cyclosporine and interleukin-4 or interleukin-10 prolongs survival of synergeneic pancreatic islet grafts in nonobese diabetic mice: islet graft survival does not correlate with mRNA levels of type 1 or type 2 cytokines, or transforming growth factor-β in the islet grafts. Transplantation 1997; 64: 1525–31.
